Related Experiment Video

Updated: May 21, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

[Gastrointestinal bleeding following ingestion of low-dose ibuprofen]

E Vaquero Sosa1, A Bodas Pinedo, C Maluenda Carrillo

  • 1Unidad de Gastroenterología Infantil, Hospital Clínico San Carlos, Madrid, España. estvaqsos@yahoo.es

Anales De Pediatria (Barcelona, Spain : 2003)
|June 22, 2012
PubMed

Insights

This study reviewed cases of pediatric gastrointestinal bleeding. Nine healthy children experienced upper gastrointestinal bleeding after receiving recommended doses of ibuprofen for fever.

Area of Science:

  • Pediatric pharmacology
  • Gastrointestinal health
  • Adverse drug events

Context:

  • Ibuprofen is a common non-steroidal anti-inflammatory drug (NSAID) for pediatric fever and pain.
  • NSAIDs are generally considered safe for short-term, low-dose use in children.
  • Emerging concerns regarding potential adverse effects necessitate further investigation.

Purpose:

  • To review cases of gastrointestinal bleeding in children.
  • To assess the risk of gastrointestinal bleeding associated with recommended ibuprofen doses.
  • To understand the incidence and presentation of upper gastrointestinal bleeding in pediatric patients.

Summary:

  • Nine previously healthy pediatric patients presented with upper gastrointestinal bleeding.
  • These patients had received weight-related, recommended doses of ibuprofen for fever management.
  • The findings indicate a potential risk of gastrointestinal bleeding even at recommended ibuprofen dosages.

Impact:

  • Highlights a potential safety concern with ibuprofen use in children.
  • Informs clinical practice regarding pediatric pain and fever management.
  • Underscores the importance of monitoring for gastrointestinal adverse events in pediatric NSAID use.
Abstract

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...